Crescent Biopharma Grants 12,525 Share Options at $25.70 Strike Price
Crescent Biopharma granted options to purchase 12,525 shares to two non-executive employees with a $25.70 exercise price and 10-year term. The awards vest one-fourth after one year and one-forty-eighth monthly thereafter, contingent on continuous service under the Inducement Plan.
1. Inducement Awards Details
The Compensation Committee approved inducement awards totaling options on 12,525 ordinary shares to two non-executive employees under the Crescent Biopharma 2025 Employment Inducement Incentive Award Plan. These grants were material to each employee’s acceptance of employment and were approved on April 23, 2026.
2. Option Terms and Vesting
Each option carries a ten-year term with an exercise price of $25.70, equal to the April 23, 2026 closing price. Vesting occurs one-fourth on the first anniversary of each employee’s start date, followed by one-forty-eighth monthly vesting, subject to continuous service.
3. Strategic Rationale and Impact
These inducement awards aim to secure specialized talent crucial for advancing Crescent’s clinical-stage oncology pipeline, including its PD-1 x VEGF bispecific antibody program. While the grants will modestly increase potential share count, they align employee incentives with long-term company performance.